Blood purification therapy for sepsis

Transfusion and Apheresis Science

Volumn 35, Issue 3, 2006, Pages 245-251

  Sakata, Hiromi ^a   Yonekawa, Motoki ^a   Kawamura, Akio ^a  

^a SAPPORO HOKUYU HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTOXIN; POLYMYXIN B;

ARTICLE; CLINICAL TRIAL; HEMODIAFILTRATION; HEMOPERFUSION; HUMAN; JAPAN; PATHOGENESIS; SEPSIS; SIGNAL TRANSDUCTION;

CYTOKINES; ENDOTOXINS; HEMOFILTRATION; HEMOPERFUSION; HUMANS; POLYMYXIN B; SENSITIVITY AND SPECIFICITY; SEPSIS;

EID: 33751571793     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2006.06.003     Document Type: Article

References (40)

1. Bone R.C., Sibbald C.L., and Sprung W.J. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101 (1992) 1481-1483
2. Ziegler E.J., Fisher Jr. C.J., Sprung C.L., Straube R.C., Sadoff J.C., Foulke G.E., et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324 (1991) 429-436
3. Fisher Jr. C.J., Slotman G.J., Opal S.M., Pribble J.P., Bone R.C., Emmanuel G., et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 22 (1994) 12-21
4. Fisher Jr. C.J., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334 (1996) 1697-1702
5. Abraham E., Wunderink R., Silverman H., Perl T.M., Nasraway S., Levy H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. Jama 273 (1995) 934-941
6. Akira K., and Takeda S. Toll-like receptor signalling. Nat Rev Immunol 4 (2004) 499-511
7. Johnson G.B., Brunn G.J., Samstein J.L., and Platt B. New insight into the pathogenesis of sepsis and the sepsis syndrome. Surgery 137 (2005) 393-395
8. Cohen J. The immunopathogenesis of sepsis. Nature 420 (2002) 885-891
9. Bone R.C., Grodzin C.J., and Balk R.A. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112 (1997) 235-243
10. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282 (1998) 2085-2088
11. Johnson G.B., Brunn G.J., and Platt J.L. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 23 (2003) 15-44
12. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 7 (2003) 108-114
13. Kodama M., Hanasawa K.T., and Tani T. Blood purification for critical care medicine: endotoxin adsorption. Ther Apher 1 (1997) 224-227
14. Tani T., Hanasawa K., Kodama M., Imaizumi H., Yonekawa M., Saito M., et al. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 activities in septic patients. World J Surg 25 (2001) 660-668
15. Vincent J.L., Laterre P.F., Cohen J., Burchardi H., Bruining H., Lerma F.A., et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23 (2005) 400-405
16. Varga K., Wagner J.A., Bridgen D.T., and Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. Faseb J 12 (1998) 1035-1044
17. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., and Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390 (1997) 518-521
18. Wang Y., Liu Y., Ito Y., Hashiguchi T., Kitajima I., Yamakuchi M., et al. Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem 294 (2001) 73-82
19. Wang Y., Liu Y., Sarker K.P., Nakashima M., Serizawa T., Kishida A., et al. Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Lett 470 (2000) 151-155
20. Ono S., Tsujimoto H., Matsumoto A., Ikuta S., Kinoshita M., and Mochizuki H. Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am J Surg 188 (2004) 150-156
21. Matsuda K., Hirasawa H., Oda S., Shiga H., and Nakanishi K. Current topics on cytokine removal technologies. Ther Apher 5 (2001) 306-314
22. Kramer P., Wigger W., Rieger J., Matthaei D., and Scheler F. [Arteriovenous haemofiltration: a new and simple method for treatment of over-hydrated patients resistant to diuretics]. Klin Wochenschr 55 (1977) 1121-1122
23. Ronco C., Bellomo R., and Ricci Z. Continuous renal replacement therapy in critically ill patients. Nephrol Dial Transplant 16 Suppl 5 (2001) 67-72
24. Hirasawa H., Sugai T., Ohtake Y., Oda S., Shiga H., Matsuda K., et al. Continuous hemofiltration and hemodiafiltration in the management of multiple organ failure. Contrib Nephrol 93 (1991) 42-46
25. Canaud B., and Mion C. Extracorporeal treatment of acute renal failure: methods, indications, quantified and personalized therapeutic approach. Adv Nephrol Necker Hosp 24 (1995) 271-313
26. Van der Schueren G., Diltoer M., Laureys M., and Huyghens L. Intermittent hemodialysis in critically ill patients with multiple organ dysfunction syndrome is associated with intestinal intramucosal acidosis. Intensive Care Med 22 (1996) 747-751
27. Mehta R.L., McDonald B., Gabbai F.B., Pahl M., Pascual M.T., Farkas A., et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 60 (2001) 1154-1163
28. Kellum J.A., Angus D.C., Johnson J.P., Leblanc M., Griffin M., Ramakrishnan N., et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 28 (2002) 29-37
29. Guerin C., Girard R., Selli J.M., and Ayzac L. Intermittent versus continuous renal replacement therapy for acute renal failure in intensive care units: results from a multicenter prospective epidemiological survey. Intensive Care Med 28 (2002) 1411-1418
30. Schetz M. Non-renal indications for continuous renal replacement therapy. Kidney Int suppl (1999) S88-S94
31. Hoffmann J.N., Hartl W.H., Deppisch R., Faist E., Jochum M., and Inthorn D. Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Kidney Int 48 (1995) 1563-1570
32. Bellomo R., Tipping P., and Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 21 (1993) 522-526
33. Oda S., Hirasawa H., Shiga H., Nakanishi K., Matsuda K., and Nakamura M. Continuous hemofiltration/hemodiafiltration in critical care. Ther Apher 6 (2002) 193-198
34. Ronco C., Ricci Z., and Bellomo R. Importance of increased ultrafiltration volume and impact on mortality: sepsis and cytokine story and the role of continuous veno-venous haemofiltration. Curr Opin Nephrol Hypertens 10 (2001) 755-761
35. Oda S., Hirasawa H., Sugai T., Shiga H., Matsuda K., and Ueno H. Cellular injury score for multiple organ failure severity scoring system. J Trauma 45 (1998) 304-310 Discussion 310-1
36. Reeves J.H., Butt W.W., Shann F., Layton J.E., Stewart A., Waring P.M., et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 27 (1999) 2096-2104
37. Cole L., Bellomo R., Hart G., Journois D., Davenport P., Tipping P., et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 30 (2002) 100-106
38. Ronco C., Bellomo R., Homel P., Brendolan A., Dan M., Piccinni P.L., et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356 (2000) 26-30
39. Kline J.A., Gordon B.E., Williams C., Blumenthal S., Watts J.A., and Diaz-Buxo J. Large-pore hemodialysis in acute endotoxin shock. Crit Care Med 27 (1999) 588-596
40. Morgera S., Slowinski T., Melzer C., Sobottke V., Vargas-Hein O., Volk T., et al. Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status. Am J Kidney Dis 43 (2004) 444-453